Inverness and Biosite make it official
This article was originally published in The Gray Sheet
Executive Summary
Definitive merger agreement calls for Inverness to buy heart test maker Biosite for $92.50 per share, valuing the company at roughly $1.58 billion based on Biosite's 17.1 million shares outstanding as of March 31. Announced May 17, the deal will require Biosite's payment of a $54 million breakup fee to its former merger partner Beckman Coulter, for which Biosite will be reimbursed by Inverness. Beckman Coulter had bid $90 per share, or about $1.54 billion based on Biosite's shares outstanding, and announced May 14 that it would not increase its offer. Diagnostics firm Inverness plans to "quickly leverage Biosite's strength in proprietary protein markers and robust cardiovascular platform together with [Inverness'] ongoing research and development efforts in the cardiac arena," states CEO Ron Zwanziger. The deal is expected to close in early summer (1"The Gray Sheet" May 14, 2007, In Brief)...
You may also be interested in...
Inverness Acquisition Surge Aims To Grow Annual Sales To $3 Billion By 2012
Inverness Medical Innovations plans to continue its recent acquisition spree with the goal of achieving $3 billion in annual revenues by the end of 2012, the company says
Inverness Continues 2007 Buying Spree, Adds Matritech Assets For $36 Mil.
Inverness Medical continues to build its worldwide distribution capabilities with the $36 million purchase of Matritech's assets, the firm's tenth acquisition or joint venture announced this year
Inverness’ even bigger bid for Biosite puts ball back in Beckman’s court
Latest salvo in the bidding war for heart test maker Biosite comes from Inverness Medical Innovations, raising its offer to $92.50 per share. Biosite recently inked an amended deal with Beckman Coulter valued at $90 per share to match Inverness' prior unsolicited proposal. Biosite says it is weighing the latest Inverness offer (1"The Gray Sheet" May 7, 2007, In Brief)...